Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,868 shares of the biopharmaceutical company's stock after acquiring an additional 561 shares during the period. Cullen Frost Bankers Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,356,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the last quarter. Tompkins Financial Corp bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Curat Global LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on REGN shares. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Trading Up 0.4%

NASDAQ:REGN traded up $2.07 on Thursday, hitting $550.00. The stock had a trading volume of 989,175 shares, compared to its average volume of 924,248. The company has a fifty day moving average price of $544.09 and a two-hundred day moving average price of $617.21. The stock has a market cap of $59.38 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 2.03 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period last year, the firm posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue was down 3.7% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.